Abstract

Human gastrointestinal malignancies are highly heterogeneous cancers. Clinically, heterogeneity largely contributes to tumor progression and resistance to therapy. Heterogeneity within gastrointestinal cancers is defined by molecular subtypes in genomic and transcriptomic analyses. Cancer stem cells (CSCs) have been demonstrated to be a major source of tumor heterogeneity; therefore, assessing tumor heterogeneity by CSC trait-guided classification of gastrointestinal cancers is essential for the development of effective therapies. CSCs share critical features with embryonic stem cells (ESCs). Molecular investigations have revealed that embryonic genes and developmental signaling pathways regulating the properties of ESCs or cell lineage differentiation are abnormally active and might be oncofetal drivers in certain tumor subtypes. Currently, multiple strategies allow comprehensive identification of tumor subtype-specific oncofetal signatures and evaluation of subtype-specific therapies. In this review, we summarize current knowledge concerning the molecular classification of gastrointestinal malignancies based on CSC features and elucidate their clinical relevance. We also outline strategies for molecular subtype identification and subtype-based therapies. Finally, we explore how clinical implementation of tumor classification by CSC subtype might facilitate the development of more effective personalized therapies for gastrointestinal cancers.

Keywords: Gastrointestinal cancer, Heterogeneity, Cancer stem cell, Cancer subtype, Precision oncology

Introduction

Worldwide, gastrointestinal cancers rank among the most frequent malignancies and are responsible for more than half of all cancer deaths. Common cancers of the gastrointestinal tract include liver, colorectal, pancreatic, gastric and esophageal malignancies. Current therapeutic treatments are ineffective, as most patients develop metastasis, resistance to radiation/chemotherapy, and recurrence. Thus, new strategies to improve treatment effects for patients with gastrointestinal cancers are urgently needed [1, 2].

Genomic and transcriptomic analyses reveal that human gastrointestinal malignancies are highly heterogeneous cancers. Clinically, heterogeneity largely contributes to tumor progression, metastasis, resistance to therapy, and relapse. Bulk tumors contain diverse tumor cell subpopulations with distinct molecular signatures that display differential levels of sensitivity to treatments. Under therapeutic stress, the expansion of intrinsic subpopulations or the evolution of drug-tolerant cells can lead to resistance to treatment. In clinical pathology, these kinds of subpopulations, drug-tolerant cells or poorly differentiated tumors usually exhibit stem-like traits and lead to adverse clinical events. Cancer stem cells (CSCs) have been demonstrated to be a major source of tumor heterogeneity. CSCs are a very heterogeneous subpopulation of “stem-like” cancer cells described...
as “tumor-initiating cells” or “sphere-forming cells” and share critical features with embryonic stem cells (ESCs), including multilineage differentiation, self-renewal and maintenance of the pluripotency state [3–5]. Specifically, the existence of molecular subtypes indicates the presence of molecular heterogeneity. Elucidation of gastrointestinal cancer classifications integrating CSC properties is critical, as such classifications may allow us to not only better understand the mechanisms of carcinogenesis from a CSC perspective but also improve diagnosis and prognostication and facilitate the development of precision medicine through identification of subtypes that may respond to specific targeted therapies. In the present review, we describe recent advances in the molecular classifications of five common gastrointestinal cancer types from the CSC perspective and elucidate their therapeutic and clinical relevance, thereby providing an overview of molecular subclassification by cancer stem cell traits for translation into clinical implementation and treatment selection.

Gastrointestinal tumor heterogeneity and therapeutic resistance

Tumor heterogeneity, therapeutic resistance, and cancer stem cell properties

Tumor heterogeneity consists of intertumor (tumor by tumor) and intratumor (within each tumor) heterogeneity. Tumor heterogeneity can arise from cells of origin. For example, PDAC (90% of all cases) and pancreatic neuroendocrine neoplasm (PanNET, 3–5% of all cases) are two major histological subtypes of pancreatic cancer. PanNET is further divided into well-differentiated pancreatic neuroendocrine carcinoma and poorly differentiated pancreatic neuroendocrine carcinoma (PanNEC). The heterogeneity among PDAC, PanNEC and PanNET can be manifested by different driver genes. The critical driver gene mutations found in PDAC include those in KRAS, CDKN2A, TP53, and SMAD4. PanNEC harbors mutations in KRAS, TP53 and RB1, while the core driver gene mutations in PanNET include alterations in MEN1, DAXX/ATRX, and mTOR pathway genes (PTEN, TSC2 and PIK3CA), which completely differ from those in PDAC and PanNET. Furthermore, the origins of PDAC, PanNET and PanNEC are complicated. Precursor cells of intralobular ducts or acinar cells with exocrine secretion can give rise to PDAC. PanNETs may originate from the α-cell lineage, β-cell lineage or islet cell precursors. PanNEC cells of origin may arise from undifferentiated progenitor cells and harbor stem cell-like properties [6]. Accumulating evidence suggests that CSCs originate from nonmalignant stem or progenitor cells [7, 8]. CSC heterogeneity has been demonstrated to be a major source of intratumor heterogeneity within each tumor population and contributes to inducing chemoresistance and subsequent tumor relapse [9–14]. Diverse subpopulations of CSCs show distinct functions, developmental statuses or gene expression profiles [15, 16]. Cellular surface markers are a useful tool to isolate and identify CSC populations. Most of the markers are derived from hematopoietic and embryonic stem cells. Some markers have been proposed as preferential stemness markers, such as Nanog, Sox2, Oct4 and c-Myc. Some markers have been described to define CSC populations in different cancer types (Table 1); for instance, the combination of CD24 and CD44 markers delineates a common CSC population for colorectal cancer, liver cancer, pancreatic cancer, and others. Interestingly, this population also characterizes the mesenchymal-like CSC population in breast cancer [17]. In addition, the expression of most CSC markers varies between tumor types and even between patients under the same subtype. For instance, CD24 showed significantly lower expression in oral squamous cell carcinoma, while CD24 had higher expression in pancreatic intraepithelial neoplasia [18]. However, marker functionality and CSC identification are still under debate because of the lack of consistency. A possibility that heterogeneity remains in purified populations remains, and the combination of multiple markers may promote optimal CSC enrichment. Indeed, EpCAM, CD166 and CD44 were more robust as markers of colorectal carcinoma (CRC) CSCs than CD133 alone [19].

CSCs display many features of ESCs because they tend to retain activation of one or several vital and highly conserved signaling pathways involved in the differentiation and pluripotency of stem cell phenotypes. CSCs can cause and sustain tumor growth, similar to ESCs, which develop into blastocysts and provide sustenance for fetal growth. They can both generate tumor cells from various stem cells and normal somatic cells. In addition, they have similar putative transcription factors (e.g., Nanog, Sox2, Oct4, Klf4, and c-Myc) and surface markers (e.g., CD133, CD90, CD24, and CD44). Furthermore, they are enriched in developmental signaling pathways regulating the features of embryonic cells or normal organogenesis or cell lineage differentiation, which may drive the initiation and progression of poorly differentiated malignancies. Five major signaling pathways have been identified as bestowing embryonic stemness traits upon tumor cells. These pathways included the Hedgehog, Hippo, Notch, TGF-β and Wnt/β-catenin pathways. All these pathways play important roles in conferring the ability of CSCs to turn into identical daughter cells by self-renewal, thereby maintaining immortality and differentiating into various types of cells. Moreover, these pathways are involved in gastrointestinal cancer initiation, migration and resistance. As CSCs are highly heterogeneous,
the expression of stemness pathways varies at different time points and in different gastrointestinal tumor types. Interestingly, activation of CSC pathways can also be identified in tumor cell expressing distinct CSC markers. For example, overexpression of Notch1 and Notch2 has been correlated with increased expression of CD44 and EpCAM in pancreatic cancer (PDAC) [20]. Wnt signaling has been shown to be activated to maintain the self-renewal and tumorigenicity of CD44+ gastric CSCs [21]. In HCC, Notch and Jagged have been shown to be highly expressed in CD133+ hepato-cellular carcinoma (HCC) CSCs [22]. To date, an increasing number of biomarkers indicating activation of CSC pathways are being discovered continuously.

CSC biomarkers and signaling pathways are critical factors distinguishing molecular classifications with stem-like traits. The expression levels plus the activation degrees of CSC biomarkers and signaling pathways differ in different subtypes, which has led to investigations into potential new avenues of targeted therapy. CSC-targeted therapies are currently in development, and many are already in clinical trials (Fig. 1; Table 2). To achieve better clinical outcomes, combination-based therapies should be implemented in CSC-targeting strategies. Moreover, CSC-directed therapy should be applied preferably early when CSC populations are still small and resistance pathways have not yet been induced. CSC-directed therapy can also be applied in various stages of the patient treatment journey.

### Tumor plasticity

Cancer cell plasticity has been proposed as one of the important mechanisms contributing to intratumor heterogeneity. Plasticity enables cancer cells to shift between a nontransformed differentiated state and a tumorigenically transformed undifferentiated or CSC state in response to microenvironmental stimuli (e.g., oncogenic stresses, senescence, and inflammation). Plasticity usually includes stem cell multilineage interconversion, dedifferentiation and transdifferentiation [23, 24]. CSCs may arise from their normal stem cells, progenitors and/or differentiated somatic cells. CSCs have the potential to differentiate into cancer cells, dedifferentiate into original lineage cells, and/or transdifferentiate into other lineage cells [25, 26]. Aberrantly activated plasticity drives malignant transformation and confers tumors to accommodate the constraints of tumor growth and therapy resistance. In our previous study, we found that CHD1L (chromo-domain-helicase-DNA-binding protein 1-like gene) is a potential clinical developmental lineage oncogene in HCC. CHD1L expression is active in the embryonic stage but decreases progressively during terminal differentiation. However, CHD1L expression is abnormally amplified in HCC. This dynamic expression pattern is accompanied by elevated liver ancestral precursor markers and reduced hepatic lineage differentiation markers. Further suppression of CHD1L may hinder poorly differentiated HCC and sensitize patients to chemotherapeutic drugs [27]. Our recently published study [28] found...
another oncofetal driver, Claudin6 (CLDN6), which has a dynamic expression pattern similar to that of CHD1L, as a potential therapeutic target correlated with HCC lineage plasticity. A high CLDN6 abundance led to a phenotypic shift of the HCC cellular subtype from a hepatic lineage to a biliary lineage, which confers sorafenib resistance. A de novo anti-CLDN6 monoclonal antibody (CLDN6-DM1) specific for CLDN6+ cells was developed. The preclinical data demonstrated the potent therapeutic efficacy of CLDN6-DM1 as a single agent or in combination with sorafenib in HCC management.

Epithelial-to-mesenchymal transition (EMT) is one of the most important processes of plasticity. The EMT program is dynamic and fundamental to embryonic development [29]. Accumulating evidence has revealed the connection between CSCs and EMT. Although whether EMT is necessary for CSCs is still under debate, EMT undoubtedly plays an important role in CSCs. First, at earlier stages of progression, depending on the microenvironmental cues, the intermediate mesenchymal states are reversible, and EMT in tumor cells may be transient, which leads to a greater plastic CSC phenotype, poorer patient survival and greater resistance to chemotherapy. For example, six different populations of EpCAM-cells identified by the CSC markers CD61, CD106 and CD51 exhibited this intermediate EMT state and more efficiently formed metastases [30]. Second, elevation of EMT master transcription factors
| Signaling pathways | Cancer types | Therapeutic agents | Targets | Phase | Combination drugs | Reference |
|--------------------|--------------|-------------------|---------|-------|------------------|-----------|
| **TGF-β signaling** |             |                   |         |       |                  |           |
| Antisense oligonucleotides | Pancreatic neoplasms, Colorectal Neoplasms | AP 12009 (Trabedersen) | TGF-β2 | Phase 1 |                  | NCT00844064 |
| TβR kinase inhibitors/small-molecule inhibitors | (1) Hepatocellular carcinoma (2) Advanced or metastatic unresectable pancreatic cancer (3) Rectal adenocarcinoma (4) Advanced hepatocellular carcinoma (5) Advanced hepatocellular carcinoma (6) Metastatic cancer and advanced or metastatic unresectable pancreatic cancer (7) Metastatic pancreatic cancer (8) Advanced refractory solid tumors; Hepatocellular carcinoma (9) Metastatic pancreatic cancer | LY2157299 (Galunisertib) | TβR (1) Phase 1 (2) Phase 1 (3) Phase 2 (4) Phase 2 (5) Phase 2 (6) Phase 1b/2 (7) Phase 1 (8) Phase 1b/2 (9) Phase 1 | (1) Sorafenib (2) Galunisertib (3) Capecitabine, Fluorouracil (4) Sorafenib (5) Sorafenib, Ramucirumab (6) Gemcitabine (7) Durvalumab (8) Nivolumab (9) Durvalumab | (1) NCT02240433 (2) NCT02154646 (3) NCT02688712 (4) NCT02178358 (5) NCT01246986 (6) NCT01373164 (7) NCT02734160 (8) NCT02423343 (9) NCT02734160 |
| **Wnt signaling** |             |                   |         |       |                  |           |
| β-catenin inhibitors | (1) Advanced pancreatic cancer; Metastatic pancreatic cancer; Pancreatic adenocarcinoma (2) Hepatitis C virus-infected cirrhosis (3) Colorectal adenocarcinoma; Stage IVA colorectal cancer; Stage IVB colorectal cancer | ICG-001(PRI-724) | CBP/β-Catenin (1) Phase 1 (2) Phase 1 (3) Phase 2 | (1) Gemcitabine (2) Bevacizumab, Leucovorin, Oxaliplatin, Fluorouracil | (1) NCT01764477 (2) NCT02195440 (3) NCT02413853 |
| Wnt antibodies | (1) Hepatocellular carcinoma (2) Pancreatic cancer; Stage IV pancreatic cancer | Ipafricept (OMP-54F28) | Fzd8-Fc fusion protein (1) Phase 1 (2) Phase 1 | (1) Sorafenib (2) Nab-Paclitaxel Gemcitabine | (1) NCT02069145 (2) NCT02050178 |
| (1) Colorectal cancer (2) Metastatic colon cancer | Foxy-5 | WNT5a receptor (1) Phase 1 (2) Phase 1 | (1) NCT02020291 (2) NCT02655952 |
| Wnt antibodies | Pancreatic cancer | Vantictumab (OMP-18R5) | Frizzled receptor | Phase 1 | Nab-Paclitaxel and Gemcitabine | NCT02005315 |
not only enforces metastatic potential but also exacerbates the tumor-initiating capacity [9, 31, 32]. Indeed, most gastrointestinal cancer subtypes with stem cell features display a strong association with the EMT phenotype.

| Signaling pathways | Cancer types | Therapeutic agents | Targets | Phase | Combination drugs | Reference |
|--------------------|--------------|--------------------|---------|-------|-------------------|-----------|
| DKK1 antibodies    | (1) Hepatocellular carcinoma (2) Esophageal neoplasms; Adenocarcinoma of the gastroesophageal junction; Gastric adenocarcinoma (3) Carcinoma of intrahepatic and extra-hepatic biliary system; Bile duct cancer; Cholangiocarcinoma | DKK1 | (1) Phase 1/2 (2) Phase 1 (3) Phase 1 | (1) Sorafenib (2) Paclitaxel or pembrolizumab (3) Gemcitabine and cisplatin | (1) NCT03645980 (2) NCT02013154 (3) NCT02375880 |
| Porcupine inhibitors | (1) Metastatic colorectal cancer (2) Pancreatic cancer; Esophageal squamous cell cancer (3) Colorectal adenocarcinoma; Gastric adenocarcinoma; Pancreatic adenocarcinoma; Bile duct carcinoma; Hepatocellular carcinoma; Esophageal carcinoma; Gastrointestinal cancer | LGK974 (WNT974) Porcupine | (1) Phase 1 (2) Phase 1 | (1) LGX818, Cetuximab (2) PDR01 | (1) NCT02278133 (2) NCT01351103 |
| Notch signaling     | (1) Metastatic pancreatic ductal adenocarcinoma (2) Locally advanced or metastatic pancreatic cancer (3) Colorectal cancer | Demcizumab (OMP-21M18) DLL4 | (1) Phase 2 (2) Phase 1 (3) Phase 1 | (1) Gemcitabine, Abraxane® (2) Gemcitabine, Abraxane® | (1) NCT02289898 (2) NCT01189929 (3) NCT01189942 |
| DLL4 antibody       | Untreated stage IV pancreatic cancer Metastatic colorectal cancer | Tarextumab (OMP-59R5) Brontictuzumab (OMP-52M51) | Notch2, Notch3 Notch1 | Phase 1/2 Phase 1 | Nab-Paclitaxel, Gemcitabine Trifluridine or tipiracil | NCT01647828 NCT03031691 |
| Notch receptor antibody | Pancreatic cancer | MK-0752 γ-secretase | Phase 1 | Gemcitabine hydrochloride | | NCT01098344 |
| γ-secretase inhibitor | (1) Metastatic pancreas cancer (2) Metastatic colorectal cancer (3) Metastatic colorectal cancer (4) Metastatic colorectal cancer | RO4929097 (R4733) γ-secretase | (1) Phase 2 (2) Phase 2 (3) Phase 1 (4) Phase 2 | (2) FOLFOX regimen, Bevacizumab, Oxaiplatin, leucovorin calcium, fluorouracil (3) Cetuximab | (1) NCT01232829 (2) NCT01270438 (3) NCT01198535 (4) NCT01166687 |

Table 2 (continued)
| Signaling pathways | Cancer types | Therapeutic agents | Targets | Phase | Combination drugs | Reference |
|--------------------|-------------|--------------------|---------|-------|------------------|-----------|
| Hedgehog signaling |             |                    |         |       |                  |           |
| SMO inhibitor      | (1) Metastatic pancreatic adenocarcinoma | Vismodegib (GDC-0449) | SMO     | (1) Phase 2 | (1) Gemcitabine, nab-paclitaxel | (1) NCT01088815 |
|                    | (2) Metastatic colorectal cancer |                    |         | (2) Phase 2 | (2) Bevacizumab, Modified FOLFOX, FOLFIRI | (2) NCT00636610 |
|                    | (3) Pancreatic adenocarcinoma |                    |         | (3) Phase 1 | (3) Gemcitabine | (3) NCT01713218 |
|                    | (4) Metastatic pancreatic cancer or solid tumors |                    |         | (4) Phase 1 | (4) Erlotinib, gemcitabine | (4) NCT00878163 |
|                    | (5) Pancreatic ductal adenocarcinoma |                    |         | (5) Phase II | (5) Vismodegib, FOLFOX, FOLFIRI, Bevacizumab | (5) NCT01096732 |
|                    | (6) Metastatic colorectal cancer |                    |         | (6) Phase II | (6) Gemcitabine hydrochloride | (6) NCT00959647 |
|                    | (7) Recurrent or metastatic pancreatic cancer |                    |         | (7) Phase II | (7) Gemcitabine hydrochloride | (7) NCT01064622 |
|                    | Metastatic gastric, gastroesophageal, esophageal adenocarcinomas | BMS-833923 (XL139) | Phase 1 | Cisplatin, capecitabine | NCT00909402 |
|                    | Esophageal cancer | Taladegib (LY2940680) |         | Phase 1/2 | Paclitaxel, carboplatin, radiation | NCT02530437 |
|                    | (1) Metastatic pancreatic cancer | Patidegib (IPI-926) |         | (1) Phase 1 | (1) Gemcitabine | (1) NCT01130142 |
|                    | (2) Advanced pancreatic adenocarcinoma |                    |         | (2) Phase 1 | (2) FOLFIRINOX | (2) NCT01383538 |
| SMO inhibitor      | (1) Esophageal cancer | Itraconazole | SMO     | (1) Phase 1 | (1) S-fluorouracil, Leucovorin, Irinotecan, Oxaliplatin | (1) NCT02749513 |
|                    | (2) Esophageal Cancer |                    |         | (2) Phase 2 | (2) Gemcitabine | (2) NCT04018872 |
|                    | (3) Locally Advanced Squamous Esophageal Cancer | Saridegib (IPI-926) |         | (3) Phase 2 | | (3) NCT04481100 |
|                    | (1) Pancreatic cancer |                    |         | (1) Phase 1 | (1) Gemcitabine, nab-paclitaxel | (1) NCT01383538 |
|                    | (2) Pancreatic cancer | Sonidegib (LDE225) |         | (2) Phase 1 | (2) Bevacizumab | (2) NCT01383538 |
|                    | (1) Resectable pancreatic adenocarcinoma |                    |         | (1) Phase 1/2 | (1) Gemcitabine, nab-paclitaxel | (1) NCT01431794 |
|                    | (2) Advanced or metastatic HCC |                    |         | (2) Phase 1 | (2) Everolimus | (2) NCT02151864 |
|                    | (3) Esophageal cancer |                    |         | (3) Phase 1 | (3) Fluorouracil, leucovorin, oxaliplatin, irinotecan | (3) NCT02138929 |
|                    | (4) Advanced pancreatic cancer |                    |         | (4) Phase 1 | (4) Fluorouracil, leucovorin, oxaliplatin, irinotecan | (4) NCT01485744 |
|                    | (5) Pancreatic cancer |                    |         | (5) Phase 1/2 | (5) Gemcitabine, nab-paclitaxel | (5) NCT02358161 |
|                    | (6) Pancreatic cancer |                    |         | (6) Phase 1 | (6) Gemcitabine | (6) NCT01487785 |
|                    | (7) Pancreatic cancer |                    |         | (7) Phase 1 | (7) Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | (7) NCT01485744 |
|                    | (8) Resectable pancreatic cancer |                    |         | (8) Phase 1 | | (8) NCT01694589 |
| Hippo signaling    | YAP inhibitor | Pancreatic cancer non-resectable | Verteporfin | YAP | Photodynamic therapy | NCT03033225 |
|                    | CSC surface markers | Anti-CD44 antibody | Malignant solid tumor | RO5429083 | CD44 | Phase 1 | NCT01358903 |
|                    |                    | CD44v6 inhibitor | Malignant solid tumor | AMC303 | CD44v6 | Phase 1 | NCT03009214 |
Identification of molecular subtypes with CSC properties in gastrointestinal malignancies

Gastrointestinal malignancies are highly heterogeneous within tumors and have been defined by identifying so-called molecular subtypes. Transcriptomic, genomic, and/or epigenomic profiling of many tumors offers the basis for molecular classification. These distinct molecular subtypes reflect different biological backgrounds, including immunity, metabolism, and stemness. Specifically, CSCs have been demonstrated to be a major source of intratumor heterogeneity. Integrative analyses of molecular subclassification from the CSC perspective may be encouraged with the aim of determining consensus molecular classification in patient prognostication and selection for therapies (Table 3).

Classification with CSC properties in liver cancer

Zhu et al. [33] used a 14-gene Notch score to stratify HCC into Notch-high HCC and Notch-low HCC subtypes. The Notch-high HCC subtype was associated with less differentiated tumors and poor survival, characterized by increased expression of progenitor/cholangiocyte markers (DCLK1 and KRT19), and highly enriched in genes related to developmental signaling and the fetal liver. In contrast, Notch-inactive HCC is a subtype of well-differentiated neoplasms with a better prognosis. In our recently published study [34], human ESCs were differentiated into human hepatocytes, and the whole differentiation process was defined by four stages: embryonic stem cells (ESs), endoderm (EN), liver progenitor cells (LPs), and premature hepatocytes (PHs). We classified liver cancer into two major subtypes based on oncofetal gene expression patterns. We defined the genes from the ES and EN groups as the embryonic-like subtype (ES+ subtype) and genes from the LP and PH groups as the liver progenitor-like subtype (LP+ subtype). Interestingly, the ES+ subtype was mainly associated with genes in the pluripotency and stem cell self-renewal signaling pathway and the Gli signaling pathway, while the LP+ subtype was mainly associated with the TGF-β signaling pathway. Moreover, genes in the Notch and Wnt signaling pathways span all four stages. Lee et al. [35] uncovered two subgroups in their study: hepatocytes (HCs) and hepatoblasts (HBs). The specific HB subtype may arise from adult hepatic progenitor cells and features elevated expression of KRT7 and KRT19. Based on the oncofetal gene expression profiling, Yamashita et al. [36] distinguished two HCC subtypes: HpSC-HCC (referred to as EpCAM+AFP+) and MH-HCC (referred to as EpCAM-AFP-). KRT19 and Wnt/β-catenin signaling are enriched in EpCAM+AFP+HCC cells. The EpCAM+ subgroup of HCC displayed a similar expression pattern to the LP+ tumors in our study. In Hoshida et al.’s study [37], HCC patients were classified into S1, S2 and S3 subgroups based on the extent of tumor differentiation. The Wnt pathway was activated in S1 tumors by a mechanism of TGF-β signature activation. Class S2 was a progenitor cell group featuring Myc and AKT activation and EpCAM and AFP enrichment. S3 tumors were notable for differentiated hepatocyte function. Most of the patients’ tumors with oncofetal properties in our
| Cancer types       | Reference     | Classifications | Signatures & Pathways (+: Activation, −: Suppression)                                                                 | Prognosis                                      | Inhibitors (+: Sensitive, −: Resistance)                                                                 |
|-------------------|---------------|-----------------|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Liver cancer      | Zhu et al. [30] | Notch-high      | Notch and TGF-β signaling, KRT19, DCLK1, SOX9 (+)                                                                 | higher tumor stage, worse survival outcome     | ES⁺: HLM6474 (+); LP⁺: SIS3 (+)                                                                 |
|                   | Liu et al. [31] | ES⁺, LP⁺        | ES⁺: pluripotency and stem cell self-renewal signaling pathways (+), Gli, Notch and Wnt pathways (+); LP⁺: TGF-β; Notch and Wnt pathways (+) |                                                               |                                                                                                  |
|                   | Lee et al. [32] | HB, HC          | HB: KRT7, KRT19, VIM, AP-1 complex (+)                                                                             | HB: tumor-invasive, worse survival, poorer prognosis |                                                                                                  |
|                   | Yamashita et al. [33] | HpSC-HCC (EpCAM⁺,AFP⁺), MH-HCC (EpCAM⁺,AFP⁻) | HpSC-HCC: KRT19, c-Myc, Wnt/β-catenin (+); MH-HCC: HepPar1 (+)                                                      | HpSC-HCC: tumor-invasive, poor prognosis       | HpSC-HCC: β-catenin inhibitor (+); EpCAM⁺ HCC cells: GSK-3β inhibitor BIO, 5-FU (−); EpCAM⁺ HCC cells: 5-FU (+) |
|                   | Hoshida et al. [34] | S1, S2, S3     | S1: Wnt, TGF-β, EMT (+); S2: Myc, AKT, EpCAM, AFP (+); S3: hepatocyte differentiation (+)                        | S1: earlier recurrence, tumor-invasive, poor survival; S2: poor survival; S3: good survival    |                                                                                                  |
|                   | Boyault et al. [35] | G1, G2, G3, G4, G5, G6 | G1: AX0N mutations, fetal liver expressing genes, AFP (+); G2: AKT (+); G3: cell cycle genes (+); G5: Wnt (+); G6: Wnt, LEF1 (+), CDH1 (−) | G4-G6: better survival VS G1-G3               |                                                                                                  |
| Colorectal cancer | Marisa et al. [36] | C1, C2, C3, C4, C5, C6 | C1: EMT (−); C2: Wnt (−); C3: EMT (−); C4: EMT (−); C5: Wnt (−); C6: EMT (+)                                      | C4 plus C6: worse prognosis VS all other subtypes |                                                                                                  |
Table 3 (continued)

| Cancer types          | Reference                      | Classifications                                                                 | Signatures & Pathways (+: Activation, −: Suppression)                                                                 | Prognosis                                                                 | Inhibitors (+: Sensitive, −: Resistance)                                                                 |
|-----------------------|--------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Colorectal cancer     | Sadanandam et al. [37]         | Enterocyte, goblet-like, inflammatory, transit-amplifying (CS-TA, CR-TA), stem-like | Goblet-like and enterocyte: differentiation markers (+), stem cell and Wnt markers (−); Transit-amplifying: stem and progenitor markers (+), Wnt-target genes (−); Stem-like: Wnt, stem cell, myoeptithelial and mesenchymal markers (+), differentiation markers (−) | Goblet-like and transit-amplifying: good prognosis; Enterocyte and inflammatory: intermediate DFS; Stem-like tumors: shortest DFS | Goblet-like: cetuximab (+); Inflammatory: FOLFIRI (+); Stem-like: cetuximab, FOLFIRI (+); CS-TA: cetuximab (+); CR-TA: cMET inhibitors (+), cetuximab (−) |
|                       | De Sousa et al. [38]           | CCS1, CCS2, CCS3                                                                | CCS1: Wnt (+); CCS3: EMT, matrix remodeling and TGF-β (<)                                                              | CCS3: poor prognosis                                                     | CCS3: cetuximab (−)                                                                                         |
|                       | Budinska et al. [39]           | Surface crypt-like, lower crypt-like, CIMP-H-like, mesenchymal, mixed            | Surface crypt-like: EMT (−), Wnt (−), β-catenin (−); Lower crypt-like: EMT (−), Wnt (+); CIMP-H-like: β-catenin (−); Mesenchymal: EphB2, EMT (+), Wnt (−), β-catenin (−); Mixed: EphB2, EMT, Wnt (+) | Surface crypt-like and lower crypt-like: better prognosis VS mesenchymal; CIMP-H-like: poor OS and SAR; Mesenchymal: recurrence risk, poor OS; Mixed: poorer SAR VS lower crypt-like |                                                                                                               |
|                       | Roepman et al. [40]            | Type A, Type B, Type C                                                           | Type A: EMT (−); Type B: EMT (−); Type C: EMT (+)                                                                      | Type A: good prognosis; Type B: poor prognosis; Type C: poor prognosis    | Type A: 5-FU (+); Type B: 5-FU (+); Type C: 5-FU (−)                                                          |
|                       | Gunney et al. [41]             | CMS1, CMS2, CMS3, CMS4                                                           | CMS1 and CMS3: RTK and MAPK pathways (+); CMS2: HNF4A, Myc and Wnt (+); CMS4: EMT, TGF-β, angiogenesis, matrix remodeling pathways (+) | CMS1: worse SAR; CMS4: worse RFS and OS                                  | CMS1: HS90 inhibitors (+); CMS2: HS90 inhibitors, EGFR inhibitors, HER2 inhibitors (+); CMS4: combination treatment of 5-FU and luminespib (+) |
| Cancer types | Reference | Classifications | Signatures & Pathways (+: Activation, −: Suppression) | Prognosis | Inhibitors (+: Sensitive, −: Resistance) |
|--------------|-----------|-----------------|------------------------------------------------------|-----------|----------------------------------------|
| Pancreatic cancer | Collisson et al. [43] | Classical, QM-PDA, exocrine-like | Classical: GATA6 (+); QM-PDA: mesenchyme associated genes (+) | Classical: good prognosis Exocrine-like: intermediate prognosis; QM-PDA: worst prognosis | Classical: erlotinib (+), docetaxel (−); QM-PDA: oxaliplatine, 5-FU, BET inhibitor (+); Exocrine-like: SN-38 (−) |
| Moffitt et al. [44] | Normal stromal, activated stroma, basal-like, classical | Activated stroma: SPARC, WNT2, WNT5A, MMP9, MMP11 (+); Classical: GATA6 (+); | Activated stroma: worse survival VS normal stroma; Basal-like: worse survival VS classical | | Normal stroma: Hedgehog pathway inhibitor (+); Basal-like: oxaliplatine, 5-FU, BET inhibitor (+); Classical: docetaxel, SN-38 (−) |
| Bailey et al. [45, 81] | Pancreatic progenitor (PP), squamous, immunogenic and aberrantly differentiated endocrine exocrine (ADEX) | Squamous: pancreatic endodermal cell fate determination genes; Hedgehog/Wnt pathway (−); TGF-β and Myc pathway (+); PP: developmental transcription factors (+); Notch pathway (+) ADEX: pancreatic developmental and differentiatial genes (+); Notch pathway (+) | PP: good survival outcomes; Immunogenic and ADEX: intermediate survival outcomes; Squamous: worst survival outcomes | | Squamous: oxaliplatine, 5-FU, BET inhibitor, GSK3β inhibitor (+); Squamous and PP subtypes: docetaxel (−); PP: SN-38 (−) |
| Biederstädt et al. [80] | Squamous/basal-like | SUMO pathway and Myc (+) | Worse prognosis | | SUMOylation inhibitor (+) |
| Mueller et al. [46] | Cluster 1, Cluster 2, Cluster 3, Cluster 4, Cluster 5 | | | | |
| Pancreatic cancer | Puleo et al. [47] | Pure classical, immune classical, pure basal-like stroma activated, desmoplastic | Stroma activated and pure basal-like: MET, Hedgehog pathway (+) | Pure classical and immune classical: good prognosis; Stroma activated and desmoplastic: poor prognosis; Pure basal-like: worst prognosis | |
| Sivakumar et al. [48] | Notch, repressed Hedgehog/Wnt, cell cycle | | Notch: best prognosis; Repressed Hedgehog/Wnt: worst prognosis | | |
| Seino et al. [49] | W⁺, W⁻, WRi | W⁺: exogenous Wnt (−), R-spondin (+); W⁻: exogenous Wnt (+), R-spondin (+); WRi: Wnt signaling (−) | W⁺: poor survival and metastatic progression | | |
| Cancer types       | Reference                  | Classifications                      | Signatures & Pathways (+: Activation, −: Suppression) | Prognosis                                                                 | Inhibitors (+: Sensitive, −: Resistance) |
|-------------------|----------------------------|--------------------------------------|-------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------|
| Gastric cancer    | Lei et al. [53]            | Proliferative, metabolic, mesenchymal | Proliferative: E2F, Myc, RAS (+); Mesenchymal: EMT, CSC pathway (+) | No significant differences among the 3 subtypes                            | Metabolite: 5-FU (+); Mesenchymal: PI3K/AKT-mTOR inhibitors (+) |
|                   | Cristescu et al. [54]      | MSI, MSS/EMT, MSS/p53 and MSS/p53    | MSS/EMT: EMT (+)                                      | MSS/EMT: worst prognosis, recurrence, stage III/IV, earlier age; MSI stage V, best prognosis |                                          |
|                   | Cheul Oh et al. [55]       | EP, MP                               | EP: Wnt (+), EMT (−), MP: EMT, IGF pathway, Hedgehog pathway (+) | EP: better survival; MP: poor survival                                 | EP: adjuvant chemotherapy (+); MP: adjuvant chemotherapy (−); IGF1/IGF1R pathway inhibitor (+) |
|                   | Cheong et al. [56]         | Epithelial, immune, stem-like        | Epithelial: CDX1 (+); Stem-like: SFRP4 (+)           | Low-risk (immune-high), intermediate-risk (immune-low and stem-like-low), or high risk (immune-low and stem-like-high) | No benefit (immune-high or immune-low and epithelial-low) or chemotherapy-benefit (immune-low and epithelial-high) |
| Oesophageal cancer| Walker et al. [57]         | ESCC1, ESCC2, ESCC3                  | ESCC1: SOX2, TP63 (+); ESCC2: ZNF750 and Notch1 mutation, CDK6 amplification (+), KDM6A and KDM2D (−), PIK3R1 and PTEN (−); ESCC3: mutations associated with RTK/RAS/PI3K pathway (+) | No significant differences between the 2 subtypes                          |                                          |
|                   | Wang et al. [58]           | Subtype I, Subtype II                | Subtype II: epithelium development genes (+)         | No significant differences between the 2 subtypes                          | Subtype 1: CDK4/6 inhibitors, docetaxel (+); Subtype 2: CDK4/6 inhibitors (+); Subtype 3: CDK4/6 inhibitors (+); Subtype 4: CDK2 inhibitors (+); |
|                   | Jammula et al. [59]        | Subtype 1, Subtype 2, Subtype 3, Subtype 4 | Subtype 1: DNA repair and cell cycle driver genes (+); Subtype 2: differentiation and developmental transcription factors (+); Subtype 4: high level of copy number alterations (+) | Subtype 1: CDK4/6 inhibitors, docetaxel (+); Subtype 2: CDK4/6 inhibitors (+); Subtype 3: CDK4/6 inhibitors (+); Subtype 4: CDK2 inhibitors (+); |

ADEX: aberrantly differentiated endocrine-exocrine; CCS: colon cancer subtype; CIMP: CpG island methylator phenotype; CMS: consensus molecular subtype; EMT: epithelial-mesenchymal transition; EP: epithelial phenotype; EpCAM: epithelial cell adhesion molecule; ES: embryonic stem cell; ESCC: oesophageal squamous cell carcinomas; FU: 5-fluorouracil; HB: hepatoblasts; HC: hepatocytes; LP: liver progenitor cell; MP: mesenchymal phenotype; MSI: microsatellite instability; MSS: microsatellite-stable; OS: overall survival; PH: premature hepatocytes; PP: pancreatic progenitor; QM-PDA: quasi-mesenchymal-pancreatic ductal adenocarcinoma; RFS: relapse-free survival; RTK: receptor tyrosine kinase; SAR: survival after relapse; VS: versus
study were consistent with the poorly differentiated S1 and S2 subgroups. Accordingly, the nononcofetal class of HCC matched the well-differentiated S3 subtype. Boyault et al.’s study [38] divided patients into G1 through G6 subgroups according to clinical and genetic characteristics. G1 and G2 tumors were characterized by AKT activation and fetal liver properties, G3 tumors were typified by activation of cell cycle genes, heterogeneous G4 tumors were associated with rare TCF1 mutations, and G5 and G6 tumors were strongly related to Wnt pathway activation.

Classification of CSC properties in colorectal cancer

Similar to other gastrointestinal cancers, considerable effort has been dedicated to colorectal cancer stemness-based subtyping. Marisa et al. [39] revealed six subtypes: C1 (21%) is characterized by suppression of pathways associated with EMT, C2 (19%) is characterized by suppression of the Wnt pathway, C3 (13%) is characterized by suppression of EMT, C4 (10%) often shows upregulation of EMT and genes related to stem cell-like signatures, C5 (27%) exhibits overexpression of Wnt pathway genes, and C6 (10%) shows upregulation of the EMT pathway. Studies performed by Sadanandam et al. [40] identified five subtypes and proposed that the five subtypes were associated with distinct cell subtypes found in normal colonic crypts. These subtypes are referred to as enterocyte, goblet-like, inflammatory, transit-amplifying, and stem-like subtypes. The transit-amplifying subtype is a heterogeneous subtype highly enriched for stem cell-relevant genes and the Wnt pathway and can be further divided into two groups based on the differential cetuximab response (CS-TA and CR-TA). Another stem-like subset is characterized by overexpression of Wnt signaling target genes and the presence of mesenchymal and myoepithelial stem-cell features, with downregulation of differentiation markers, whereas the goblet-like and enterocyte subsets are enriched in well-differentiated genes with few stem cell characteristics and low Wnt marker expression. In De Sousa et al. [41], they revealed three colon cancer subtypes: CCS1, CCS2 and CCS3. CCS1 (49%) refers to tumors with high activity of the Wnt signaling cascade, while CCS3 (27%) corresponds to heterogeneous and poorly differentiated tumors with upregulation of EMT, matrix remodeling and the TGF-β pathway. Unlike traditional molecular classification according to gene expression profiling, Budinska et al. [42] applied meta-gene profiles to identify five major subsets: surface crypt-like, lower crypt-like, CIMP-H-like, mesenchymal and mixed. Surface crypt-like and lower crypt-like subtypes are well differentiated with low expression of the EMT/stroma gene module when the mesenchymal subtype and the mixed subtypes are enriched for high expression of the EMT/stroma gene module. In addition, the lower crypt-like and mixed subsets highly expressed Wnt signaling target signatures along with higher β-catenin nuclear immunoreactivity. In contrast, surface crypt-like and mesenchymal subgroups showed low expression of these signatures along with lower β-catenin nuclear immunoreactivity. Moreover, the CIMP-H-like subtype exhibited almost no β-catenin nuclear immunoreactivity and low expression of gut development genes. Another classification based on whole-genome analysis of CRC patients in stages I-IV was discovered by Roepman et al. [43], who unveiled three molecular subtypes: Type A, Type B and Type C. Type A (22%) corresponds to a DNA mismatch repair (MMR)-deficient epithelial subtype, Type B (62%) represents an epithelial proliferative subtype, and Type C (16%) is characterized by the expression of EMT-related molecules. Intriguingly, these three subtypes overlapped with the three subtypes distinguished by De Sousa et al.

The above CRC subtyping systems considered three to six molecular subtypes with different characteristics that might lack compatibility and lead to some confusion. To standardize the different molecular subtypes, a large-scale study of 4000 CRC samples mainly in stages II-III was performed [44] to identify four distinct molecular classifications that correctly classified 78% of the samples: CMS1 (14%, MSI immune), CMS2 (37%, canonical), CMS3 (13% metabolic) and CMS4 (23% mesenchymal). CMS2 is characterized by epithelial differentiation and strong activation of the Wnt and Myc signaling pathways. CMS4 is characterized by EMT upregulation, activation of TGF-β signaling, enhanced matrix remodeling, complement-mediated inflammation and angiogenesis. In addition, NOTCH3 is a putative target for advanced CMS4 CRC patients [45]. CMS1-4 may reasonably be similar to any of the molecular subtypes mentioned above. CMS1 may fit the CCS2 class from De Sousa and the inflammatory class from Sadanandam. The class CMS2 consensus may be related to the CCS1 subtype from De Sousa and to the enterocyte and/or transit-amplifying subtypes from Sadanandam. The CMS4 subset can be associated with CCS3 tumors from De Sousa and with the stem-like module defined by Sadanandam.

Classification of CSC properties in pancreatic cancer

Collisson et al.’s study [46] described three subtypes: classical, quasi-mesenchymal (QM-PDA) and exocrine-like. The classical subtype is enriched in GATA6, while the QM-PDA subtype has comparatively low GATA6 expression. GATA6 is essential for pancreatic development and differentiation. Moffitt et al. [47] extended the work from Collisson et al. by defining two subtypes for the tumor tissue (classical and basal-like) while adding stromal classifications (normal and activated). The classical subtype
overlaps with Collison’s classical subtype and is characterized by elevated GATA6 expression. In addition, “activated” stroma is characterized by genes relevant to tumor promotion, such as the secreted protein SPARC, MMP family members MMP9 and MMP11, and WNT family members WNT2 and WNT5A. More recently, Bailey et al. [48] defined four molecular subtypes of PDAC: pancreatic progenitor (PP), squamous, immunogenic and aberrantly differentiated endocrine-exocrine (ADEX). The squamous subset entails downregulation of genes that control pancreatic endodermal cell fate determination, repression of Hedgehog/Wnt signaling, and TGF-β signaling and MYC pathway activation. The PP subtype is characterized by developmental transcription factors and enrichment of Notch signaling. The ADEX class is enriched with genes that are important in lineage specification and later stages of pancreatic development and differentiation. Intriguingly, a spectrum of differentiation that resembles embryonic lineages from early progenitors to fully differentiated cells exists in these subtypes. The Collison and Bailey classifications overlapped fairly well, with the exception of the immunogenic subtype. The Collison classical subtype is similar to the PP subtype, the QM-PDA subtype is similar to the squamous subtype, and the exocrine-like subtype is similar to the ADEX subtype. Following Bailey et al.’s study, Mueller et al. [49] defined five distinct clusters based on evolutionary trajectories and KRAS gene dosage. Cluster 1 resembles the squamous subtype. Clusters 2 and 5 are associated with epithelial cell differentiation and embryonic development. Cluster 3 is enriched for undifferentiated tumors and characterized by EMT and Ras downstream signaling. Cluster 4 is enriched for undifferentiated tumors and corresponds to the immunogenic subtype. Another subtyping study from Puleo et al. [50] further distinguished five subtypes: pure classical, immune classical, pure basal-like, stroma activated and desmoplastic. The pure classical subtype is well differentiated (low-grade G1) and similar to the classical and PP subtypes. The pure basal-like subtype is poorly differentiated (high-grade G3) and associated with metastatic spread. The other subtypes correspond to an intermediate differentiation grade. The immune classical and desmoplastic subtypes fit Moffitt’s ‘normal stroma’ subtype, while the pure basal-like and stroma activated subtypes fit Moffitt’s ‘activated stroma’ subtype. Furthermore, the MET and Hedgehog signaling pathways are both activated in the stroma and pure basal-like subtypes.

Researchers have also classified PDAC based on CSC-related signal transduction pathways. In Sivakumar et al.’s study [51], three main biological processes generated by the transcriptional signatures of oncogenic KRAS-specific master regulators were identified: Notch, repressed Hedgehog/Wnt, and the cell cycle. All three subtypes represent three different transcriptional programs during PDAC development and are linked to the Bailey subtypes. Suppression of Hedgehog/Wnt signaling is involved in the squamous subtype, Notch signaling is enriched in the ADEX and PP subtypes, and the cell cycle process is overrepresented by samples from the immunogenic subtype. Seino et al. [52] unveiled three subtypes based on the Wnt signaling pathway from a tumor organoid library: W+(Wnt-secreting organoids), W- (Wnt-nonsecreting organoids) and WRi (Wnt and R-spondin-independent organoids). The W+ subtype is independent of exogenous Wnt ligands but requires R-spondin, the W- subtype depends on exogenous Wnt and R-spondin ligands, and the WRi subtype is Wnt signaling-independent.

Notably, potential overlap of defined subtypes may exist. Interestingly, plasticity occurs in these subtypes; that is, one subtype can switch to another, such as squamous to ADEX conversion [53, 54]. In mouse models, tumors shifted from squamous to classical after BET inhibitor treatment [55]. Another example is GATA6-mediated subgroup switching, as GATA6 downregulation contributes to the QM-like subtype in PDAC [48]. Conversely, GATA6-high PDACs exhibit higher levels of epithelial Wnt ligands, indicating GATA6-regulated Wnt niche dependency in patients with PDACs [52].

**Classification of CSC properties in gastric cancer**

Lei et al. [56] unveiled three subtypes in their study: proliferative, metabolic, and mesenchymal. The mesenchymal subtype harbors CSC-like properties with the following four features. First, this subtype is strongly associated with CSC pathway activation. Second, it shows high CD44 and low CD24 levels compared with other types, which is similar to the QM-PDA subtype of PDAC. Third, it maintains an undifferentiated state, which is an essential feature of CSCs. Finally, the hypermethylated gene sets significantly overlap with genes expressed at low levels in HCC harboring hepatic stem cell properties. In addition, the proliferative subtype shows elevated activities for several oncogenic pathways: E2F, MYC, and RAS. Cristescu et al. [57] used gene expression data to describe four patient subsets of gastric cancer: MSI, MSS/EMT, MSS/p53+ and MSS/p53−, where MSS refers to microsatellite stable tumors. The MSS/EMT module was significantly correlated with the EMT signature. Another Korean study led by Oh et al. [58] distinguished two distinct molecular subtypes: the epithelial phenotype (EP) and mesenchymal phenotype (MP). Higher recurrence rates reflecting the clinical consequences of EMT were shown for the MP subtype, as the EMT-promoting pathway (TGF-β, Hedgehog pathway) and proteins
Classification of CSC properties in esophageal cancer

Esophageal cancer includes two main histological types: esophageal adenocarcinomas (EACs) and esophageal squamous cell carcinomas (ESCCs). In contrast to studies on other gastrointestinal tract tumors, molecular classification studies of esophageal cancer are currently lacking. Walker et al. [60] unveiled three molecular subtypes: ESCC1, ESCC2, and ESCC3. ESCC1 tumors show high amplification of SOX2 and TP63. SOX2 is a pluripotent stem cell transcription factor that favors the development and maintenance of squamous epithelia. ESCC2 tumors contain more ZNF750 and NOTCH1 mutations, inactivation of the histone demethylases KDM6A and KDM2D, deactivation of the PIK3CA suppressors PIK3R1 and PTEN, and CDK6 amplification. The last group, ESCC3, contains mutations forecasting activation of the RTK/RAS/PI3K pathway. Another study performed by Wang et al. [61] revealed two distinct subtypes of ESCC. Subtype I entails a highly activated pathway involved in the immune response, while subtype II is enriched in pathways involved in ectoderm development. Epithelium development genes, including E2F4, JUN, KRT5 and KRT14, were enriched in Subtype II. PDPN and SIX1 have high expression levels in Subtype II ESCC, while SIX1 can maintain or increase PDPN-positive CSCs. Specifically, they discovered potential ESCC subset-specific diagnostic markers: EYA2 and FOXA1 for subtype I and KRT14 and LAMC2 for subtype II, which may help guide ESCC clinical treatment. Most recently, Jammula et al. [62] identified four subtypes from Barrett’s esophagus and EAC. Subtype 1 showed elevation of driver gene alterations (CCND1, CCNE1, MYC, CDK6). Subtype 2 displayed significant overexpression of sets of key master transcription factors correlated with differentiation and development, including HNF4A/G, FOXA1/2/3, GATA6 and CDX2. Subtype 3 was enriched in all pathways related to immune regulation, while subtype 4 contained a high quantity of copy number alterations. Considering the obvious parallels existing in these three classifications by Walker, Wang and Jammula, the extent of connection among the three classifications remains to be fully addressed.

Common events of gastrointestinal subtypes

Cancer stem cell properties are included in molecular classification systems for gastrointestinal cancers. Most classifications are characterized by similar stem cell traits, poor differentiation, and poor clinical outcomes. Most gastrointestinal tumors appear to belong to subgroups with EMT traits, for example, the C4, CCS3, mesenchymal, type C and CMS4 subsets in CRC, the cluster 3 and pure basal-like subgroups in PDAC, and the MSS/EMT and MP subtypes in gastric cancer. Another consistently identified subtype is characterized by the activation of signaling pathways involved in ESC differentiation and pluripotency, such as the Wnt pathway, TFG-β pathway, Hedgehog pathway and Myc pathway. For instance, the Wnt pathway is enriched in the C5, C6, transit-amplifying, stem-like, CCS1 and CMS2 subgroups in CRC, in the ‘activated’ stroma and W+ subgroups in PDAC, and in the EP subgroup in gastric cancer. Additionally, most classifications reflect the original functions of ESCs characterized by overexpression of key developmental and differentiation factors, for example, our ES and LP subtypes in liver cancer and the PP, squamous, ADEX, Cluster 2 and Cluster 5 subgroups in PDAC.

Notably, genetic mutations also contribute to the tumor stemness phenotype. For instance, ESCC2 esophageal cancers are enriched for NOTCH1 mutations, and mutations in ESCC3 drive activation of the RTK/RAS/PI3K pathway, indicating that genomic and transcriptomic subtypes interact with each other. Integrating both genomic and transcriptomic information may help identify the related entities or entities with common origins. Furthermore, according to clinical observations of poorly differentiated gastrointestinal cancers with preserved lineage characteristics of their developmental precursor cells, such tumors may progress to acquire classifiable phenotypes, and the similarities between tumor subtypes from different organs may be defined from early embryonic development events that are reflected in the developmental signaling expression or mutational profiles of classified tumors. The inter- and intratumor heterogeneity caused by these events can be used to foster patient welfare.

Evaluating strategies for subtype-directed therapy

Subtyping identification strategies

The tumor heterogeneity of each subtype is mainly explored by multiomics (transcriptomics, proteomics, metabolomics, lipidomics, glycomics) in many publicly available repositories (such as TCGA, ICGC and GEO) or institutional sources. For example, Liu et al.
performed unsupervised clustering to define three immune subtypes with different features from multiple HCC databases and developed a support vector machine (SVM) classifier based on multiomics signatures, and this multiomics SVM model provided potential predictors for prognosis and responses to immunotherapy in HCC [63]. Molecular subtyping typically requires tissue biopsy samples. However, subtyping strategies may be hampered by the following aspects. First, in some hardly accessible tumors, such as PDAC, omics-based subtype classifications are difficult to obtain; in this case, small classifiers can be devised to circumvent this problem by working on small amounts of tumor tissues from routine diagnostic cytology. Second, intratumor heterogeneity may lead to sampling error and possibly tumor misclassification, and developing marker panels or blood-based markers for tumor subtypes can help circumvent these problems [64]. Recently, liquid biopsy has become an appealing non-invasive clinical tool for the isolation and detection of blood-based markers. Jose et al. [65] provided an example to apply a microfluidic platform to identify CSC subtypes (CD133+CK+CD45−DAPI+EpCAM+ and CD133+CK+CD45−DAPI+EpCAM−) from patient blood samples in PDAC. Liquid biopsy can overcome the difficulties of obtaining tissue biopsies, capture spatial and/or temporal heterogeneity, and facilitate therapy response monitoring [66]. However, multiple technical issues, especially insufficient sensitivity and specificity, still need to be solved for future clinical application.

To date, markers for tumor subtypes can be measured using flow cytometry, real-time quantitative polymerase chain reaction (qPCR), and immunohistochemical or immunofluorescent staining [67]. In addition, recent achievements of single-cell techniques such as scRNA-seq (single-cell RNA sequencing) have provided extraordinary insights into intratumor heterogeneity, which has already been highlighted in cancer classification, diagnosis, and treatment [68]. scRNA-seq can be used to characterize rare but important subtypes. For example, Daniel et al. [16] revealed a novel stemness-related cell subclone (CD24+/CD44+) within EPCAM+HCC cells, and suppression of the signature gene CTSE in CD24+/CD44+ cells abrogated the self-renewal ability of HCC. Lin et al. [69] applied scRNA-seq to identify the EMT+PDAC subtype and epithelial tumor cell (ETC) population. The reported high mesenchymal gene expression signals (i.e., QM subtype) were enriched in the EMT+ subtype, and the signature genes defining the classic, progenitor and squamous subtypes were enriched in the ETC population, whereas the signature genes defining the basal subtype were enriched in both EMT and ETC tumor cells.

**Preclinical models for subtype therapy**

Various drug sensitivity studies have been performed using the most common models, such as tumor-derived cell lines and patient-derived xenografts (PDXs), which can retain the common molecular characteristics of primary tumors and generate valuable transcriptomic information for molecular subtypes and corresponding clinical and pharmacological data for association studies. Several large-scale studies have been performed on a large set of tumor-derived cell lines for biomarker discovery and drug response prediction. Stefano et al. [70] screened the most commonly used liver cancer cell lines, including 34 models, and in combination with screening 31 anticancer agents, identified markers of therapeutic response. Another promising technique for large-scale functional screening using RNAi or CRISPR/Cas9 has also been applied to study cancer subtypes. For example, Robert et al. [71] performed a large-scale RNAi screen in 398 cancer cell lines to elucidate the vulnerabilities of specific cancer subtypes. Although tumor-derived cell lines are easily manipulated and acceptable for stem cell-based subtype identification and high-throughput screening, 2D culture cannot fully reproduce the native 3D microenvironment of tumor cells. Instead, the PDX model more reliably recapitulates patient subtypes than 2D culture by retaining patient histopathological and molecular features. Researchers have successfully translated the CMS classification of CRC to preclinical PDX models for targeted treatment and distinguished patients with poor clinical consequences within the CMS groups [72–74]. However, the shortcomings of long engraftment periods and low engraftment efficiency hamper large-scale drug screening with PDX models. Alternatively, spheroids are used as important 3D preclinical models to test the effects of targeted drugs, especially to investigate the interaction between pharmacological and radiotherapeutic strategies. For example, Che et al. [75] established co-cultured pancreatic stellate cells/PDAC heterospheroids and found that this model exhibited higher resistance to gemcitabine than PDAC-only spheroids. The role of dCK in gemcitabine resistance was further studied by using this model. Another useful 3D preclinical model is organoids. Cancer-derived organoids are good in vitro models that capture tumor subtype heterogeneity, enable therapeutic screening and encompass unique subsets required for precision medicine development. Helen et al. [76] established a human gastric cancer organoid biobank that encompassing the most known molecular subtypes. Takashi et al. [52] developed a pancreatic tumor organoid library and identified three subtypes.
based on the stem cell niche factor associated with Wnt and R-spondin. Genetically engineered models appear to be another preclinical platform to evaluate molecular subtypes and therapeutic responses; however, they are unlikely to benefit patients whose tumors lack the target [77–80].

Clinical relevance and subtype-driven therapies
Liver cancer subtypes
Zhu et al. [33] used a 14-gene Notch score to sort Notch-active signatures. Notch-active HCCs were found to resemble cholangiocarcinoma (CC)-like HCC and exhibit higher tumor stages and poorer prognoses than Notch-inactive HCCs. Notch signaling is best known for its role in cell fate determination. An overwhelming number of studies have shown that Notch signaling plays promoting roles in carcinogenesis and tumor progression; therefore, patients with cancer may benefit from Notch pathway blockade. Currently, multiple Notch inhibitors against γ-secretase, Notch receptors or ligands have been developed, including γ-secretase inhibitors, siRNA and monoclonal antibodies. The combination of Notch inhibitors with other chemotherapy or radiotherapy holds considerable promise for achieving better curative effects [81]. As a detailed subclassification of stem cell-like tumors is lacking, we established new classification models to mimic the whole differentiation process from human ESCs to human hepatocytes and classified HCC patients into two subtypes based on stem-like expression patterns. E2F1 and SMAD3 are two important oncofetal drivers of liver tumors with defined gene signatures. HCC patients with the ES-like subtype were more sensitive to the E2F1 inhibitor HLM6474, while HCC patients with the LP-like subtype were more sensitive to the SMAD3 inhibitor SIS3, indicating that targeting specific oncofetal drivers may promote drug selectivity and eliminate tumorigenicity effectively [34]. Lee et al. [35] uncovered a fetal HB subtype that might arise from hepatic progenitor cells with a poor prognosis. Another stemness-based HCC classification was proposed by Yamashita and colleagues [36]. The EpCAM+AFP+HCC subgroup harbored progenitor features with a poor prognosis, while the EpCAM-AFP-HCC subset had adult hepatocyte features with a good prognosis. Moreover, β-catenin inhibitors were more effective in EpCAM+HCC cells than in EpCAM- HCC cells in vitro. In addition, a GSK-3β inhibitor and 5-fluorouracil (FU) increased the EpCAM+ population in HCC cells. Based on the extent of tumor differentiation, Hoshida et al. [37] classified HCC patients into S1, S2 and S3 subgroups. Subclass S1 is linked with a higher risk of early recurrence, with more satellite lesions and vascular invasion. As TGF-β boosts Wnt activity by altering the subcellular localization of β-catenin, cotargeting TGF-β and β-catenin may be an effective strategy for the treatment of the S1 subclass of HCC. S2 tumors demonstrate Myc and AKT activation, suggesting that AKT or PI3K inhibitors might be valuable in this particular subclass. In contrast, the S3 subclass contains the majority of well-differentiated tumors, which tend to have a lower grade and better survival outcomes.

Colorectal cancer subtypes
In Sadanandam et al’s study [40], the goblet-like and transit-amplifying subtypes showed a good prognosis, the enterocyte and inflammatory subtypes were associated with intermediate disease-free survival (DFS), while the stem-like tumors corresponded to the shortest DFS but were shown to benefit more from FOLFIRI than others, while CS-TA and CR-TA tumors were sensitive to cetuximab and cMET inhibitor treatment, respectively. De Sousa et al. [41] compared the clinical characteristics of CCS1 and CCS3 tumors in their study and found that patients with CCS1 tumors had a good prognosis. CCS3 tumors harbored malignant potential at an early stage of adenomas and were refractory to anti-EGFR therapy. Budinska et al. [42] assessed the associations of their classifications with patient survival. Surface crypt-like and lower crypt-like subgroups showed a better prognosis. CIMP-H-like and mesenchymal subtypes were associated with poor overall survival (OS), while the former was also associated with short survival after relapse (SAR). The mixed subgroups showed a trend toward the worst OS. Molecular classification performed by Roepman et al. distinguished three subclasses [43]; Type A has the best prognosis, Type B has an intermediate prognosis but can benefit from adjuvant 5-FU chemotherapy, and Type C showed the worst survival and resistance to 5-FU-based chemotherapy. When assessing the existence of core subtype gene expression patterns among available CRC subtyping algorithms, four consensus molecular subtypes were observed to be related to clinical characteristics [44]. CMS1 patients are usually diagnosed at higher pathologic grades and show worse survival after relapse. Conversely, CMS2 patients had superior survival rates after relapse, whereas CMS4 patients had worse relapse-free and overall survival and were more likely to be in stage III and stage IV. Recently, Sveen et al. [72] translated this CMS system to preclinical models containing CRC-derived cell lines and PDX models to perform high-throughput in vitro drug screening. They found that CMS2 tumors were strongly responsive to EGFR and HER2 inhibitors and that CMS1 and CMS2 tumors were highly sensitive to HSP90 inhibitors. Furthermore, combination treatment with 5-FU and luminespib could relieve chemoresistance in CMS4 patients.
Pancreatic cancer subtypes
In Collisson et al's study [46], among the three subtypes that they described, the classical subtype had a better prognosis than the other two types, while patients with QM-PDA subtype tumors had the worst prognosis. For subtype-specific drug responses, the classical subtype was more sensitive to erlotinib. Moffitt et al. [47] defined two major subtypes for the tumor (classical and basal-like) and stromal classifications (normal and activated). Patients with the activated stroma subtype had a worse median survival than those with the normal stroma subtype. Inhibition of the Hedgehog pathway could accelerate the development of PDAC and promote the delivery of chemotherapy in the normal stromal subtype. In addition, patients with the basal-like subtype had a worse medium survival than those with the classical subtype; however, the former type showed a better response to adjuvant therapy than the classical subtype. More recently, Bailey et al. [48] published four subtypes as described above. The squamous subtype is correlated with significantly worse clinical outcomes. Some patients in the PP subgroup had better survival outcomes than those in the immunogenic and ADEX subgroups. Multivariate analysis found that this classification exhibited independent prognostic value [82]. A comprehensive analysis of drug sensitivity in the above three classifications (Collisson, Moffitt and Bailey) showed that the QMPDA, basal-like and squamous subtypes are sensitive to oxaliplatin and 5-FU. The activated stroma, QM-PDA and squamous subtypes show more resistance to gemcitabine than the ADEX subtype and Collisson's and Moffitt's classical tumor subtypes. Collisson's and Moffitt's classical subtypes and Bailey's squamous and PP subtypes are resistant to docetaxel. PP, Collisson's exocrine-like and Moffitt's classical subtypes are resistant to SN-38. When comparing gene expression in different subtypes, the QM-PDA, basal-like and squamous subtypes strongly expressed Myc, indicating that these subtypes may be more sensitive to BET inhibitors. EGFR signaling has been reported to enhance cancer cell stemness [83, 84]; although PDAC cells frequently present high EGFR expression, most are easily resistant to anti-EGFR treatment. Combined targeted therapy may help overcome this resistance. Moreover, Biederstädt et al. [85] detected coactivation of MYC and SUMO in the basal-like/squamous subtype of PDAC, which is known to be resistant to chemotherapies. SUMOylation inhibitor-based therapies might be a potential strategy to target this aggressive PDAC subtype. Specifically, Brunton et al. [86] found that loss of HNF4A and GATA6 could lead to a plasticity switch from the classical (progenitor) subtype to the squamous subtype and elevated expression of lyogen syn-thase kinase 3 beta (GSK3β). GSK3β inhibitors showed selective sensitivity in the squamous subtype; however, a subgroup of squamous patient-derived cell lines (PDCLs) acquired drug tolerance and had access to the WNT gene program. In addition, another developmental transcription factor, HNF1A, is a novel regulator of pancreatic cancer stem cell properties, and HNF1A+ tumors (non-QM, overlap with the exocrine/ADEX subtype) benefit more from FOLFIRINOX than gemcitabine-based treatment [87]. Puleo et al. [50] redefined subtypes of PDAC into five groups. The pure classical and immune classical subclasses had similar good prognoses. The patients in the stroma-activated and desmoplastic subgroups had a severe prognosis when pure basal-like tumors had the worst outcome. The Hedgehog pathway was highly enriched in stomal activated and pure basal tumors, suggesting that Hedgehog inhibitors may help prolong survival in PDAC patients with tumors in these two subgroups. In another study [51], three subtypes generated by the transcriptional signatures of oncogenic KRAS-specific master regulators were identified: Notch, repressed Hedgehog/Wnt, and the cell cycle. Evidence of the potential clinical importance of the three groups revealed that the Hedgehog/Wnt group had the worst prognosis, while the Notch group showed the best prognosis. Seino and colleagues [52] established a library of PDAC-derived organoids and identified heterogeneous subtypes dependent on Wnt ligands. They found that epithelial Wnt molecules (Wnt3, Wnt7a, Wnt7b, and Wnt10a) could serve as a surrogate marker for Wnt-producing PDACs. Notably, WRi and W+ organoids displayed higher levels of epithelial Wnt gene expression than W-organoids, and high expression of epithelial Wnt molecules was closely linked to markedly poor survival and metastatic progression.

Gastric cancer subtypes
Lei et al. [56] developed a robust classification of primary gastric adenocarcinomas: proliferative, metabolic, and mesenchymal. Analysis of survival information showed no significant differences in survival among the three subgroups. Patients with proliferative- and mesenchymal-subtype tumors did not benefit from 5-FU treatment. In contrast, mesenchymal-subtype gastric cancer cells were preferentially sensitive to PI3K-AKT-mTOR inhibitors, possibly because this subtype of cells resembles CSCs. This finding is consistent with the observation that PI3K-AKT-mTOR inhibitors are also effective in prostate cancer and glioblastoma [88, 89]. High levels of CD44 are another distinctive feature of the mesenchymal subtype. CD44 is a well-known surface biomarker of CSCs and is aberrantly expressed in a variety of tumors in the forms of CD44s (standard isoform) or CD44v (variant isoform). A high abundance of
CD44 is closely associated with a malignant phenotype and poor clinical outcomes. CD44-positive cancer cells displayed lower sensitivity to sorafenib and 5-FU. Targeting CD44 may be a promising therapeutic strategy for cancer management. CD44 antibodies and blockade of the HA-CD44 balance offer therapeutic interventions to effectively impair the properties of CSCs among various cancers [90].

Cristescu et al. [57] investigated the clinical relevance of their four molecular subtypes and found that the age at occurrence of the MSS/EMT subtype was significantly lower than that of the other subtypes. Most subjects with this subtype were diagnosed at a late stage (III/IV) and showed the worst prognosis and the highest recurrence frequency among the four subtypes. Oh et al. [58] described two subtypes: MP and EP. Clinically, the MP subtype is associated with significantly poor survival, a high recurrence rate, and resistance to standard adjuvant chemotherapy. The EP subtype is correlated with better survival and sensitivity to adjuvant chemotherapy. Importantly, MP-subtype cancer cells are significantly more sensitive to linsitinib treatment than EP-subtype cancer cells. Cheong et al. [59] uncovered three subtypes (immune, stem-like, and epithelial) for patients with resectable stage II-III gastric cancer and then developed a prognosis-based single-patient classifier to divide patients into low-risk (immune-high), intermediate-risk (immune-low and stem-like-low), or high risk (immune-low and stem-like-high) groups. They also developed a prediction-based single-patient classifier to divide patients into no-benefit (immune-high or immune-low and epithelial-low) or chemotherapy-benefit (immune-low and epithelial-high) groups. The association between the prognostic single-patient classifier groups and 5-year OS was significant. Furthermore, the association between the predictive single-patient classifier groups and adjuvant chemotherapy response in terms of OS was also notable. Collectively, the MSS/EMT, MP, and stem-like subtypes have the worst prognosis in terms of clinical consequences for multiple cohorts, highlighting the significance of stemness-based subsets requiring clinical intervention.

**Esophageal cancer subtypes**

Clinically, molecular classification studies of esophageal cancer are still limited. Jammula et al. [62] unveiled four subtypes relevant to therapy. Subtype 1 was sensitized to CHFR, which is a cell cycle checkpoint inhibitor. In addition, CDK4/6 inhibitors were effective across all subtypes, whereas CDK2 inhibitors were preferentially effective toward subtype 4 patients.

**Conclusions**

Our understanding of gastrointestinal cancer biology has drastically improved. The main genetic changes and tumor subtypes are gradually becoming well established, and their clinical relevance is being clarified. Evident distinctions are present in the biological features and clinical properties of gastrointestinal cancers, which are probably a result of heterogeneity. Clinically, heterogeneity largely gives rise to tumor progression, metastasis, resistance to therapy, and relapse. Molecular heterogeneity arises from the existence of molecular subtypes. Due to the notable effect of CSCs on heterogeneity, CSC traits are undoubtedly tightly associated with molecular classifications. Interestingly, CSCs usually resemble embryonic stem cells, which signifies the importance of developmental signals in cancer initiation and therapeutic resistance. Therefore, integrating the molecular subtypes associated with stemness properties may offer new insights into treatment resistance.

Although molecular classifications based on CSC traits are substantially expanding our understanding of gastrointestinal malignancies, the implementation of effective precision medicine is still hindered by some problems. First, sufficient studies describing the stemness-based molecular subtypes of each gastrointestinal cancer are lacking, and consensus subtypes may be identified and confirmed in future cancer expression data. Second, reliable biomarkers corresponding to molecular subtypes to predict the response to current therapies are also lacking. Newer more effective approaches should be developed and applied in the detailed characterization of intra- and intertumoral heterogeneity, such as scRNA-seq and relevant preclinical models. Further precise targeting of tumor-initiating steps and driving events according to subtype-specific biomarkers might serve as a novel therapeutic strategy in gastrointestinal cancer treatment. Finally, systematic tumor and liquid biopsy techniques should be developed to define signature molecules allowing delineation of the complete molecular profile and patient classification.

In summary, we provide an overview of molecular classifications from the CSC perspective that may facilitate improvement in the clinical management of patients with gastrointestinal malignancies and thus result in more favorable outcomes.

**Abbreviations**

ADEX: Aberrantly differentiated endocrine-exocrine; CCS: Colon cancer subtype; CHD11: Chromodomain-helicase-DNA-binding protein 1-like gene; CIMP: CpG island methylator phenotype; CLDN6-DM1: Anti-CLDN6 monoclonal antibody conjugated with cytotoxic agent (Mertansine) DM1; CMS: Consensus molecular subtype; CRC: Colorectal carcinoma; CSC: Cancer stem cell; EAC: Oesophageal adenocarcinomas; EMT: Epithelial-to-mesenchymal transition; EN: Endoderm; EP: Epithelial phenotype; EpCAM: Epithelial cell adhesion receptor
molecule; ESC: Embryonic stem cell; ESCC: Oesophageal squamous cell carcinomas; FU: 5-Fluorouracil; HB: Hepatoblasts; HC: Hepatocytes; HCC: Hepatocellular carcinoma; LP: Liver progenitor cell; MP: Mesenchymal phenotype; MSI: Microsatellite- instable; MSS: Microsatellite-stable; OS: Overall survival; PDAC: Pancreatic cancer; PDXs: Patient-derived xenografts; PH: Premature hepatocytes; PP: Pancreatic progenitor; QM-PDA: Quasi-mesenchymal-pancreatic ducal adenocarcinoma.

Acknowledgements
Not applicable.

Authors’ contributions
MML wrote the manuscript with assistance from JY. XYG and NFM gave valuable comments. ML initiated the study and finalized the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (No. 82003773).

Availability of data and materials
Not applicable.

Declarations

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China. 2 Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University, Xinzao, Pan Yu District, Guangzhou 511436, China. 3 State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. 4 Department of Clinical Oncology, State Key Laboratory of Liver Research, University of Hong Kong, Hong Kong, China.

Received: 16 July 2021 Accepted: 5 November 2021
Published online: 13 November 2021

References
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreatic cancers in the United States. Cancer Res. 2014;74(11):2913–21.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
3. Hadjimichael C, Chanoumidou K, Papadopoulou N, Arampatzi P, Papametakis I, Kretsovali A. Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells. 2015;7(9):1150–84.
4. Taniguchi H, Moriya C, Igashiri H, Saitoh A, Yamamoto H, Adachi Y, et al. Cancer stem cells in human gastrointestinal cancer. Cancer Sci. 2016;107(11):1556–62.
5. Steinbichler TB, Dudas J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova I. Therapy resistance mediated by cancer stem cells. Semin Cancer Biol. 2018;53:156–67.
6. Gao H-L, Wang W-Q, Xian-Jun Yu, Liu L. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Exp Hematol Oncol. 2020;9:28.
7. Atashzar MR, Bahrarouf R, Karami J, Abbodlali H, Rezaei R, Pourramezan F, et al. Cancer stem cells: a review from origin to therapeutic implications. J Cell Physiol. 2020;252(2):790–803.
8. Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells—a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–32.
9. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–34.
10. Craig AJ, van Felden J, Garcia-Lezana T, Sarcognoto S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatology. 2020;17(3):139–52.
11. Bekaii-Saab T, El-Rayes B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer-Am Cancer Soc. 2017;123(8):1303–12.
12. Zhou P, Li B, Liu F, Zhang M, Wang Q, Liu Y, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Mol Cancer. 2017;16(1):52.
13. Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells from the crypt to the clinic. Cell Stem Cell. 2014;15(6):692–705.
14. Islam F, Gopalani V, Wahab R, Smith RA, Lam AK. Cancer stem cells in oesophageal squamous cell carcinoma: identification, prognostic and treatment perspectives. Curr Rev Oncol Hematol. 2015;9(6):119–19.
15. Fletcher RB, Das D, Ngai J. Creating Lineage Trajectory Maps Via Integration of Single-Cell RNA-Sequencing and Lineage Tracing: Integrating transgenic lineage tracing and single-cell RNA-sequencing is a robust approach for mapping developmental lineage trajectories and cell fate changes. Bioessays. 2018;40(8):e1800056.
16. Ho DW, Tsui YM, Sze KM, Chan LK, Cheung TT, Lee E, et al. Single-cell transcriptomics reveals the landscape of intra-tumour heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett. 2019;459:176–85.
17. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014;2(1):78–91.
18. Ghuwalewala S, Ghatak D, Das P, Dey S, Sarkar S, Alam N, et al. CD44(high)CD24(lo) molecular signature determines the cancer stem cell and EMT phenotype in oral squamous cell carcinoma. Stem Cell Res. 2016;16(2):405–17.
19. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104(24):10158–63.
20. Wang Z, Zhang Y, Baneree S, Li Y, Sarkar FH. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer. 2006;118(8):1930–6.
21. Wang B, Liu J, Ma LN, Xiao HL, Wang YZ, Li Y, et al. Chimeric S5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling. J Gastroenterol. 2013;48(7):798–808.
22. Wang XQ, Zhang W, Lua EL, Zyu Y, Lu P, Xu Y, et al. Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer. 2012;131(3):E163–72.
23. Da SV, Lorenzo-Sanz L, Bernat-Peguera A, Lopez-Cerdà M, Munoz P. Cancer cell plasticity: impact on tumor progression and therapy response. Semin Cancer Biol. 2018;53:48–58.
24. Huang Z, Wu T, Liu K, Ouyang G. Differentiation and transdifferentiation potentials of cancer stem cells. Oncotarget. 2015;6(37):39550–63.
25. Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. Bmb Rep. 2017;50(3):117–25.
26. Latvia JD, Mack SC, Mulkearns-Hubbert E, Valentim CL, Rich NJ. Cancer stem cells in glioblastoma. Genes Dev. 2015;29(12):1203–17.
27. Liu M, Chen L, Ma NF, Chow RK, Li Y, Song Y, et al. ChD1I1 promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors. Hepatology. 2016;63(5):1544–59.
28. Kong FE, Li GM, Tang YQ, Xi SY, Loong J, Li MM, et al. Targeting tumor plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med. 2021;13(579):eabj8628.
29. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.
30. Thompson EW, Nagaraj SH. Transition states that allow cancer to spread. Nature. 2018;556:442–4.
31. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou Y, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
32. Ye X, Lai WM, Shibue T, Kaygusuz Y, Reinhardt F, Ng E, et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature. 2015;525(7568):256–60.
33. Zhu C, Ho YJ, Salamoa MA, Dapeto DH, Bartolomea A, Schwabe RF, et al. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathological features. J Hepatol. 2021;74(3):613–26.
34. Liu M, Yan Q, Sun Y, Nam Y, Hu L, Loong JH, et al. A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncopetals and therapeutic targets. Proc Natl Acad Sci USA. 2020;117(11):6103–13.
35. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12(4):410–6.
36. Yamashita T, Ji J, Budhu A, Forges M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.
37. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptomic analysis reveals common molecular subtypes of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–92.
38. Boyault S, Rickman DS, de Reynies A, Balbaud C, Rebouissous S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52.
39. Marisa L, de Reynies A, Duvall A, Selves J, Gaub MF, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PloS Med. 2013;10(5):e1001453.
40. Sadanandam A, Lyssiotis CA, Harnsicko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–25.
41. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroneterology. 2013;145(3):554–65.
42. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56.
43. Oh SC, Sohn BR, Cheong JH, Kim SB, Lee JE, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9(1):1777.
44. Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018;19(5):629–38.
45. Walker RC, Underwood TJ. Molecular pathways in the development and treatment of oesophageal cancer. Best Pract Res Clin Gastroenterol. 2018;32(6):797–812.
46. Wang F, Yan Z, Li J, Xin J, Dang Y, Sun X, et al. Gene Expression profiling reveals distinct molecular subtypes of esophageal squamous cell carcinoma in Asian populations. Neoplasia. 2019;21(6):571–81.
47. Julmula S, Katz-Summerscorn AC, Li X, Linnos R, Smyth E, Killcoyne S, et al. Identification of subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptomic and genome data. Gastroenterology. 2020;158(6):1682–97.
48. Luong L, Liu Q, Song J, Yuan C, Liu Y, et al. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol. 2020;9:10.
49. Bjelma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2017;14:333–42.
50. Varillas JJ, Zhang J, Chen K, Barnes II, Liu C, George TJ, et al. Microfluidic isolation of circulating tumor cells and cancer stem-like cells from patients with pancreatic ductal adenocarcinoma. Theranostics. 2019;9(5):1417–25.
51. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415–21.
52. Lathia J, Liu H, Matei D. The clinical impact of cancer stem cells. Oncolist. 2019;25(2):123.
53. Qian M, Wang DC, Chen H, Cheng Y. Detection of single cell heterogeneity in cancer. Semin Cell Dev Biol. 2017;64:143–9.
54. Lin W, Noel P, Borazanci EE, Lee J, Amiri A, Han IW, et al. Single-cell transcriptomic analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med. 2020;12(1):80.
55. Caruso S, Calatayud AL, Pilet J, La Bella T, Rekk S, Imbeaud S, et al. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastroenterology. 2019;157(3):760–76.
differentiation in colorectal adenocarcinoma. World J Gastroenterol. 2009;15(18):2258–64.

114. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;3(3):313–23.

115. Kahler C, Bergmann F, Beck J, Welsch T, Mogler C, Herpel E, et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 2011;11:275.

116. Xia S, Feng Z, Qi X, Yin Y, Jin J, Wu Y, et al. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Med Oncol. 2015;32(1):358.

117. Chen S, Huang J, Liu Z, Liang Q, Zhang N, Jin Y. FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogene. 2017;36(3):e300.

118. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–7.

119. Takaiishi S, Okumura T, Tsu S, Wang SS, Shisibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27(5):1006–20.

120. Lau WM, Tang E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014;74(9):2630–41.

121. He H, Chen W, Wang X, Wang C, Liu F, Shen Z, et al. Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci. 2012;103(7):1296–303.

122. Bu Z, Zheng Z, Zhang L, Li Z, Sun Y, Dong B, et al. LGR5 is a promising biomarker for patients with stage I and II gastric cancer. Chin J Cancer Res. 2013;25(1):79–89.

123. Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z, et al. Fzrdized? promotes epithelial-to-mesenchymal transition and stemness via activating canonical Wnt/beta-catenin pathway in gastric cancer. Int J Biol Sci. 2018;14(3):280–93.

124. Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsu moto G, et al. Characterization of biomarkers of tumorigenic and chemore sistant cancer stem cells in human gastric carcinoma. Clin Cancer Res. 2010;16(23):6156–67.

125. Nguyen PH, Graud J, Chambonner L, Dubus P, Wittkop L, Belleann ee G, et al. Characterization of biomarkers of tumorigenic and chemoresistant cancer stem cells in human gastric carcinoma. Clin Cancer Res. 2017;23(18):4523–7.

126. Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+CD24− in gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679–86.

127. Lu L, Wu M, Sun L, Li W, Fu W, Zhang X, et al. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved. Medicine. 2016;95(42):e5163.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions